Mirai Medical Ltd, a manufacturer of a precision cancer therapy platform , today announced the first procedures in the clinical trial to evaluate ePORE® therapy and EndoVE®, a novel breakthrough technology that can treat gastrointestinal cancers endoscopically in an outpatient setting with minimum hospitalisation for the patient.
The first procedure in the VECTOR trial (NCT04649372) was performed this week at Nottingham NHS Trust, United Kingdom in a team led by Mr. Simon Parsons. The VECTOR trial aims to establish the safety and efficacy of treating patients with inoperable oesophageal cancer or gastric cancer in an outpatient setting, using an endoscopic system EndoVE® to facilitate greatly enhanced low dose chemotherapy tumour absorption.